Pegfilgrastim biosimilar - USV

Drug Profile

Pegfilgrastim biosimilar - USV

Alternative Names: PEG G-CSF biosimilar - USV; Pegylated filgrastim biosimilar - USV; Pegylated-granulocyte colony stimulating factor biosimilar - USV

Latest Information Update: 04 Mar 2016

Price : $50

At a glance

  • Originator USV
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte colony stimulating factor stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Neutropenia

Most Recent Events

  • 16 Nov 2016 Phase-III clinical trials in Neutropenia in India (SC) (CTRI2014-09-005007)
  • 18 Jun 2015 Phase-III clinical trials in Neutropenia in Bulgaria, Hungary (SC) (EudraCT2015-000266-64)
  • 08 May 2015 USV files for a patent application for Pegfilgrastim before May 2015 (USV product pipeline, May 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top